What's Happening?
Effective November 16, 2026, the U.S. Food and Drug Administration (FDA) has officially transitioned from using the terms 'Artificial Intelligence' (AI) to 'Super Intelligence' (SI) in its public-facing documents, digital communications, and web portals.
This administrative change is in direct response to White House Executive Order 14434, signed by President Trump on September 29, 2026, which mandates executive departments and regulatory agencies to adopt the new terminology. The FDA has clarified that this nomenclature shift is purely administrative and does not alter existing regulatory requirements, review standards, or submission pathways for medical product sponsors and academic clinical trial investigators. The legal scope of 'Super Intelligence' under this order aligns with the statutory definition of artificial intelligence established in 15 U.S.C. 9401(3) by the National Artificial Intelligence Initiative Act of 2020, meaning it does not imply a higher capability threshold or require a demonstration of theoretical superintelligence. The new terminology applies prospectively to newly published communications from November 16, 2026, while legacy guidance documents remain in effect under their original text. Medical device manufacturers and researchers are not required to rebrand products or revise existing submissions.
Why It's Important?
This terminology change by the FDA, driven by Executive Order 14434, signifies a broader federal effort to standardize language around advanced computing technologies. While the FDA emphasizes that the change is terminological and does not impact regulatory burdens or review processes, it could have implications for public perception and the framing of future policy discussions. The shift from 'Artificial Intelligence' to 'Super Intelligence' might suggest a more advanced or impactful technological landscape, potentially influencing public and investor confidence in AI-driven medical innovations. For the industry, the FDA's clear guidance that no mandatory external rebranding or changes to submission processes are required is crucial, preventing potential disruptions and additional costs. However, the move highlights the evolving nature of regulatory language in rapidly advancing technological fields and the need for clear communication to avoid confusion among stakeholders, including developers, researchers, and the public. The White House Office of Science and Technology Policy (OSTP) is expected to propose statutory amendments to Congress to harmonize definitions across federal law, indicating a long-term commitment to this new terminology.
What's Next?
The FDA's implementation of the 'Super Intelligence' terminology is the initial phase of a broader, incremental rollout across the agency. Web developers and communications teams will continue to update online guidance, educational materials, and public directories through early 2027. Forthcoming draft guidance documents, including updates on life-cycle management for adaptive clinical algorithms, will formally incorporate the new terminology. The White House Office of Science and Technology Policy (OSTP) is tasked with drafting proposed statutory amendments for Congress to align definitions across Title 15 and Title 21 of the United States Code. The FDA also plans to continue collaborating with international regulatory partners, such as the International Medical Device Regulators Forum (IMDRF) and the World Health Organization (WHO), to ensure that these domestic terminology changes do not disrupt multilateral consensus on machine learning safety and algorithmic validation. This suggests a concerted effort to integrate the new terminology while maintaining international cooperation and regulatory consistency.
Beyond the Headlines
The shift in terminology from 'Artificial Intelligence' to 'Super Intelligence' could subtly influence public and scientific discourse, potentially raising expectations or concerns about the capabilities and ethical implications of advanced algorithms. While the FDA states the change is administrative, the term 'Super Intelligence' inherently carries connotations of greater autonomy, capability, and potential impact, which might shape future public policy debates, funding priorities, and even public trust in these technologies. This rebranding could also be seen as a strategic move to position the U.S. at the forefront of advanced technological development, signaling a commitment to fostering innovation in this area. However, it also underscores the challenge of regulating rapidly evolving technologies, where even the language used to describe them can become a point of policy and public interest. The emphasis on maintaining existing regulatory standards despite the name change is critical to ensuring continued innovation without creating unnecessary hurdles or confusion for the medical technology sector.













